Advances in Radiation Oncology

Radiation Therapy in King County, Washington During The COVID-19 Pandemic: Balancing Patient Care, Transmission Mitigation and Resident Training --Manuscript Draft--

Manuscript Number:	ADVANCESRADONC-D-20-00061R1		
Article Type:	Brief Opinion		
Section/Category:	COVID-19		
Corresponding Author:	Tru-Khang Trong Dinh, MD University of Washington Seattle, WA UNITED STATES		
First Author:	Tru-Khang Trong Dinh, MD		
Order of Authors:	Tru-Khang Trong Dinh, MD		
	Eric Ford, PhD		
	Lia M. Halasz, MD		
	Ramesh Rengan, PhD, MD		
Abstract:	COVID-19 is now a global pandemic that is advancing at a pace that threatens to rapidly overtake medical infrastructures. For the United States, most public health experts worry that this outbreak will continue to escalate, at least in the short term. With this backdrop, cancer care remains an essential clinical need, for which timely radiation therapy is a cornerstone modality. In this article, we report our experience with delivering high-quality, patient-centered radiotherapy at an epicenter of the COVID-19 pandemic within the USA. Our aim is to describe policies and procedures which we have found helpful for our own patient population, staff, and community.		

Cover Letter

To The Editor-in-Chief:

We are pleased to submit our correspondence entitled "Radiation Therapy in King County, Washington During The COVID-19 Pandemic: Balancing Patient Care, Transmission Mitigation and Resident Training" for consideration of publication in Advances in Radiation Oncology. We believe that our perspective as a radiation oncology department at an epicenter of the pandemic in the USA would be of timely interest to your readers.

Sincerely,

Khang T. Dinh, MD,

On behalf of the article co-authors.

TITLE: Radiation Therapy in King County, Washington During The COVID-19 Pandemic: Balancing Patient Care, Transmission Mitigation and Resident Training

AUTHORS:

Tru-Khang T. Dinh, MD¹ (Corresponding Author)

Email: tktdinh@uw.edu

Lia M. Halasz, MD¹

Email: lhalasz@uw.edu

Eric Ford, PhD1

Email: eford@uw.edu Ramesh Rengan, PhD, MD¹ Email: rengan@uw.edu

¹Department of Radiation Oncology, University of Washington

1959 NE Pacific Street Mailstop Box 356049 Seattle, WA 98195

Conflicts of Interest: There are no conflicts of interest with this commentary.

Funding: None

Acknowledgements: None

1 Title: Radiation Therapy in King County, Washington During The COVID-19 Pandemic: Balancing

Patient Care, Transmission Mitigation and Resident Training

On December 31, 2019, a cluster of cases of severe respiratory syndrome was reported in patients with connection to a seafood market in Wuhan, Hubei Province, China¹. Within one week, Chinese health authorities were able to link these cases to a novel, enveloped RNA coronavirus, SARS-CoV-2, now commonly known to cause COVID-19². By February 14, 2020, over 66,000 cases of COVID-19 were reported in China³. On January 19, a 35-year-old man returning from Wuhan to his home in Snohomish County, Washington, presented to urgent care with several days of cough and fever and ultimately tested positive for COVID-19, becoming the first case in the United States. The first COVID-related death occurred 4 weeks later, associated with a separate site, along-term care facility in Kirkland, WA, which rapidly became a cluster of 30 fatal cases as of March 16th. At the writing of this article, March 17th, there are 1,012 confirmed cases in the state of Washington, with 52 deaths, primarily in King County. Evergreen Health, the major medical center in Kirkland has recently declared that they have no remaining critical care capacity.

COVID-19 is now a global pandemic that is advancing at a pace that—without immediate attenuation—will rapidly overtake medical infrastructures. This has been painfully evinced in regions of Italy and Iran. For the United States, public health experts worry that this outbreak will continue to escalate, at least in the short term⁴. With this backdrop, cancer care remains an essential clinical need, for which timely radiation therapy is a cornerstone modality. Concurrently, patients with cancer may have a 5-fold relative risk for severe manifestations, such as requiring invasive ventilation or death, compared to the general population⁵. In this article, we report our experience with delivering high-quality, patient-centered radiotherapy at an epicenter of the COVID-19 pandemic within the USA. Our aim is to describe policies and procedures which we have found helpful for our own patient population, staff, and community.

The Department of Radiation Oncology at the University of Washington is comprised of seven sites of practice, in both hospital-based and outpatient, including community, settings, across the Seattle-Puget Sound area. On average, more than 220 patients are treated each day in our department, with cases ranging in complexity from whole-breast radiotherapy to immunocompromised, pediatric patients requiring anesthesia. Immediately after the public announcement of the presence of COVID-19 in our community, our department serially instituted policies and procedures which synthesized national, state, and institution-specific infection control guidance within a Radiation Oncology-appropriate model. Three overlapping goals to mitigate transmission while continuing to deliver high-quality treatments were

identified: social distancing, preservation of the pool of health care providers, and conservation of personal protection equipment.

While pharmacological interventions remain on the horizon, social distancing is the most effective known tool in curtailing the spread of this infection. Using an extended susceptible, latent, infectious, and removed (SEIR) constitutive model fitted to empirical data from the outbreak in China, biostatisticians at the Broad Institute and Harvard University have shown that social distancing methods, ranging in aggressiveness from a city-wide lockdown to centralized quarantine, was effective in dampening the reproductive number of COVID-19, ultimately controlling of the outbreak in Wuhan ⁶. In our application, employees who can perform duties remotely (e.g. research coordinators, research residents, administrative staff, and some medical physics staff) are instructed to work from home. The minimum level of staffing to maintain safe treatments at each practice site is deployed based on patient volume and complexity. Meetings have been limited to 5 persons or less, with at least 6 feet of distance between any two individuals. Nearly all tumor boards have transitioned to virtual conferencing, with the exception of small meetings with 5 persons or less, and one tumor board in which in-person coordination was felt indispensable to patient care. In this regard, our institution has expanded teleconferencing capacity to be able to support up to 50,000 simultaneous online conferences. Crucially, during the relatively short roll-out of distancing policies, a relatively user-friendly teleconferencing solution was promulgated. This empowered any single user to initiate an individualized, HIPAA-compliant teleconference session on demand.

In order to reduce exposure where possible, new patient consultations for treatment of indolent or benign conditions are deferred at the discretion of the radiation oncologist. Routine follow-ups are offered to patients via telephone or postponed. At an institutional level, providers are being quickly certified for telemedicine, with proposals to temporarily relaxed billing standards.

In terms of the safety of patients, the department has taken a number of early actions to limit the spread of coronavirus to and from patients while still allowing treatments to continue. A site visit to our clinics by our institution's infection control team was highly valuable, and this experience directly led to specific interventions that bolstered the continued treatment of patients while mitigating transmission risk. This session incorporated end-to-end patient tracing to identify opportunities to mitigate patient-to-patient, patient-to-staff, and staff-to-staff transmission. Screening of patients and staff for upper respiratory symptoms (fever, cough, rhinorrhea) is crucial for infection control. At many of our sites, there are multiple ports of entry into the clinic. As such, all patients are screened twice: once upon entering the building and again upon entering the department. Patients who are screened positive for symptoms are asked to wear a mask, are placed in a private room where they are evaluated by a provider

over telephone, and appropriately triaged. Details of our testing algorithm specific to our patient population can be found in Figure 1. All patients are asked to either thoroughly wash their hands or use effective hand sanitizers upon entering and leaving an exam or treatment room.

Fortunately, while all radiotherapy patients are screened, few have required testing, and none have tested positive thus far. As radiation therapy is often a necessary part of lifesaving cancer care, we anticipate treating patients with presumed or proven COVID-19. For the standard treatment, our institution has recommended droplet precautions (surgical mask, goggles, gloves, gown) and use of a private waiting room. These patients will be treated at the end of the day, in a particular vault that is extensively decontaminated afterwards. For treatments with anesthesia, the risk of aerosol transmission is high, and airborne precautions are required (N-95 mask, face shield, gloves, gown, personal respirator in some instances). At our main facility, a negative-pressure vault is available for treating patients requiring airborne precautions.

The rate of consumption of personal protective equipment (PPE) has been high and is expected to greatly increase in our facilities. Prior to implementing stringent conservation protocols, the University of Washington Medical Center exhausted 3 months of PPE supply in 3 days. To conserve PPE, we have instituted policies limiting the number of providers required to come into direct contact with patients with suspected or confirmed COVID-19.

Recent data suggests that COVID-19 remains viable on plastic surfaces for up to 72 hours⁷. Radiation treatment devices thus serve as a potential transmission nidus. To mitigate this risk, immobilization devices such as VakLok bags are individually disinfected and wrapped in a plastic bag that is sealed and changed after each daily use (Figure 2). Other hardware which comes into direct patient contact, such as treatment tables and positioning aides are extensively disinfected between patients. For respiratory motion management, we have developed a protocol for the use of the Active Breathing Controller (ABC, Elekta Inc.) which is used at several centers. Some elements of this device cannot be decontaminated so the device will not be used in patients with suspected or confirmed COVID-19, and abdominal compression will be used instead.

Despite having no COVID-positive patients undergoing radiotherapy as of yet at our centers, healthcare provider depletion is becoming a pressing issue. Within our department, at least 4 physicians were required to undergo testing after a self-administered online survey for low-grade symptoms. While they were all ultimately found to be uninfected, this process removed them from patient care for at least 48 hours. These disruptions can be expected to continue, and likely increase.

In these trying times, the training of medical and physics residents remains fundamental to our department's mission. Balancing training and the principles of social distancing, provider preservation, and PPE conservation is a delicate task. While immersion and availability have been beneficial tenets of training, they are subsumed by the need to mitigate transmission. Residents on a research block or on days without patient visits are instructed to work from home. All lectures and didactic activities have moved to videoconference. Most difficult of all due to our collective appreciation of time with patients, redundant encounters requiring both residents and attendings to see the patient are encouraged to be minimized. With specific focus on trainees, there are valuable lessons from prior viral epidemics. After the 2003 SARS epidemic in Toronto, trainees who were quarantined reported high levels of psychological distress, particularly those who were not contacted during their isolation for wellness checks⁸. Effective rather than effusive communication from hospital leadership was found to facilitate coping. Coherent communication is uniquely important to trainees who often straddle all sites of practice within a radiation oncology program. Empowering trainees to stay home if they have symptoms should be of utmost concern; during the 2009 H1N1 outbreak, 67% of residents with influenza-like illness still reported to work at a US training hospital, despite perceiving the risk of H1N1 transmission to be high⁹. It is imperative to have clear messaging from departmental leadership regarding expectations while simultaneously allaying concerns of any detriment to professional development as a result of missing work.

The potential disruptions to training and professional development are understandably a source of anxiety for trainees. At UW, we attempt to allay some of these concerns by regular, quarterly meetings as well as one-on-one meetings between the residents and the chair. Our department also recognizes that many of our residents and faculty have young children and face tremendous challenges as schools and childcare services have begun shutting down in the Seattle area. Further, some have partners who are internal medicine trainees who have already been asked to directly care for COVID-19 patients, or cover clinics so others may do so as the healthcare provider pool becomes depleted. Many trainees have neither the resources to hire personal back-up care nor the social network to summon pro bono care. As a response, we have initiated a grassroots effort to pool childcare resources within the UW medical community. Many university and medical students on academic furlough due to the pandemic have volunteered to serve as childcare resources specifically to healthcare providers.

We intend the above experiences to be descriptive rather than prescriptive and strongly encourage everyone to follow guidance from The Centers for Disease Control and State Department of Health, as well as guidelines from their home institution, hospital, or clinic. This pandemic, along with our institutions' response to it, are dynamic in nature. Thus, a nimble set of solutions, tailored to the specific

- needs of any single institution's patient population and those of its healthcare community is required. The
- strengths of the field of radiation oncology remain incandescent in the face of this approaching storm:
- team-based care, evidence-based practice, and a community of talented, dedicated, and compassionate
- professionals. Despite the unprecedented challenge, we intend to come together to deliver the best
- possible care for the patients who depend on us. We must also remember to support as well as to lean on
- one another during this historic trial.

136

137

REFERENCES


- 138 1. World Health Organization. Pneumonia of unknown cause China. WHO (2020). Available at:
- https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/. (Accessed: 17th March 2020)
- Guan, W. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med.
 (2020). doi:10.1056/NEJMoa2002032
- Johns Hopkins University Center for Systems Science and Engineering (CSSE). Wuhan coronavirus (2019-nCoV) global cases. Available at:
- https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b4
 8e9ecf6. (Accessed: 17th March 2020)
- Fauci, A. S., Lane, H. C. & Redfield, R. R. Covid-19 Navigating the Uncharted. *N. Engl. J. Med.* NEJMe2002387 (2020). doi:10.1056/NEJMe2002387
- Liang, W. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. The
 Lancet Oncology 21, 335–337 (2020).
- Lin, X. Analysis of 25,000 Lab-Confirmed COVID-19 Cases in Wuhan: Epidemiological
 Characteristics and Non-Pharmaceutical Intervention Effects. (2020).
- van Doremalen, N. *et al.* Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. *N. Engl. J. Med.* NEJMc2004973 (2020). doi:10.1056/NEJMc2004973
- Rambaldini, G. *et al.* The Impact of Severe Acute Respiratory Syndrome on Medical House Staff A Qualitative Study. doi:10.1111/j.1525-1497.2005.0099.x
- 9. May, L., Katz, R., Johnston, L., Sanza, M. & Petinaux, B. Assessing physicians' in training attitudes and behaviors during the 2009 H1N1 influenza season: A cross-sectional survey of medical students and residents in an urban academic setting. *Influenza Other Respi. Viruses* 4,
- 160 267–275 (2010).

161

162

163 Figure 1: COVID-19 and influenza testing decision tree for the outpatient radiotherapy population. ¹Respiratory symptoms: cough, shortness of breath, wheezing or chest tightness, sore throat. Consider 164 excluding symptoms attributable to allergies. ²High risk patients: All transplant and immunotherapy, all 165 166 hematologic malignancy, all active chemotherapy, neutropenia (ANC < 500). ³Medical comorbidities: 167 Age > 60, diabetes, CKD, pregnancy, lung cancer, chronic lung disease, cirrhosis. ⁴Other 168 immunosuppressed: biologic agents for immunosuppression, steroids > 0.5mg/kg/day prednisone 169 equivalent, congenital or acquired immunodeficiency 170 Figure 2: Patient immobilization devices (VakLok molds) are individually sealed in plastic bags which 171 172 are changed daily after treatment. 173 174

Clinical Criteria	SARS-COV-2 PCR Test?	Rapid Flu/RSV or Extended Respiratory Viral PCR Test?	Infection Control Precautions
No Fever or Respiratory Symptoms	No	No	Standard Precautions
Fever WITHOUT Respiratory Symptoms	No * Yes for Solid Organ Transplant patients <u>unless</u> <u>another known source of fever</u> <u>known</u>	No	Standard Precautions *Solid organ transplant patients with fever: Droplet/Contact Precautions IF COVID-19 is possible
Respiratory Symptoms ¹ WITH OR WITHOUT Fever	Yes: • High-risk patients ² • Patients staying in cancer center housing • Any Solid Organ Transplant Patients • Patients with high-risk medical comorbidities ³ • Other Immunosuppressed Patients ⁴	Yes: Extended Respiratory Viral PCR Test • High-risk patients ² • Lung Transplant Patients Rapid Flu/RSV Testing Only • Other Solid Organ Transplant Patients • Other Immunosuppressed Patients ⁴ • Patients with high-risk medical comorbidities ³	Mask patient and place in private room. Droplet/Contact Precautions



Click here to access/download

Uniform Disclosures Form

Dinh_COI.pdf

Click here to access/download

Uniform Disclosures Form

Rengan_COI.pdf

Click here to access/download

Uniform Disclosures Form

Ford_COI.pdf

Click here to access/download

Uniform Disclosures Form

Halasz_COI.pdf